Sunday, December 13, 2020 9:27:20 PM
No Raf, it is to say that these vaccines have not been tested properly. The clinical studies have not been completed.
(just think about if AMRN would have gotten this red carpet treatment at the FDA instead of being hamstrung and ambushed time and again we would have been the best selling heart drug of choice for 8 years running - instead we were asked to add on more and more years of research in spite of proven safety and efficacy!)
In contrast the vaccines gotten preferential treatment by the FDA and the EUA was granted on ridiculous pressure from the Trump administration in face of all these concerns :
https://www.cnbc.com/2020/12/11/white-house-threatens-to-fire-fda-chief-unless-covid-vaccine-oked-friday-report.html
Moreover this process was corrupted by the fact that former executives of these same companies were instrumental as members of the Trump administration to push this through in an unprecedented manner. To call this a conflict of interest is the most daring understatement:
https://www.nytimes.com/2020/05/20/health/coronavirus-vaccine-czar.html
https://www.salon.com/2020/05/18/trumps-new-coronavirus-vaccine-czar-owns-10-million-in-stock-options-in-company-developing-vaccine/
https://www.marketwatch.com/story/big-pharma-is-taking-big-money-from-us-taxpayers-to-find-a-coronavirus-vaccine-and-charge-whatever-they-want-for-it-2020-06-24
In any case I am deeply worried that these vaccines will cause more problems than solve them.
And specifically for what concerns us as AMRN stakeholders I wish the FDA would back us up now that we have seen how fast they can cut corners if the head of the FDA gets threatened to be fired..
(just think about if AMRN would have gotten this red carpet treatment at the FDA instead of being hamstrung and ambushed time and again we would have been the best selling heart drug of choice for 8 years running - instead we were asked to add on more and more years of research in spite of proven safety and efficacy!)
In contrast the vaccines gotten preferential treatment by the FDA and the EUA was granted on ridiculous pressure from the Trump administration in face of all these concerns :
https://www.cnbc.com/2020/12/11/white-house-threatens-to-fire-fda-chief-unless-covid-vaccine-oked-friday-report.html
Moreover this process was corrupted by the fact that former executives of these same companies were instrumental as members of the Trump administration to push this through in an unprecedented manner. To call this a conflict of interest is the most daring understatement:
https://www.nytimes.com/2020/05/20/health/coronavirus-vaccine-czar.html
https://www.salon.com/2020/05/18/trumps-new-coronavirus-vaccine-czar-owns-10-million-in-stock-options-in-company-developing-vaccine/
https://www.marketwatch.com/story/big-pharma-is-taking-big-money-from-us-taxpayers-to-find-a-coronavirus-vaccine-and-charge-whatever-they-want-for-it-2020-06-24
In any case I am deeply worried that these vaccines will cause more problems than solve them.
And specifically for what concerns us as AMRN stakeholders I wish the FDA would back us up now that we have seen how fast they can cut corners if the head of the FDA gets threatened to be fired..
Recent AMRN News
- Form ARS - Annual Report to Security Holders • Edgar (US Regulatory) • 04/10/2026 09:01:34 PM
- Form DEF 14A - Other definitive proxy statements • Edgar (US Regulatory) • 04/10/2026 09:00:20 PM
- American College of Cardiology (ACC) Scientific Sessions 2026 Underscore the Need for Complementary Therapies Including Icosapent Ethyl (IPE) in Treatment of Elevated Triglycerides and Cardiovascular Risk Reduction • GlobeNewswire Inc. • 04/08/2026 12:00:00 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 04/02/2026 08:30:11 PM
- Form PRE 14A - Other preliminary proxy statements • Edgar (US Regulatory) • 03/30/2026 09:57:06 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 03/27/2026 09:00:07 PM
- Amarin Highlights Guideline Recommended Role of Icosapent Ethyl in Managing Cardiovascular Risk Following Release of Updated 2026 ACC/AHA/Multisociety Dyslipidemia Guideline • GlobeNewswire Inc. • 03/18/2026 12:30:00 PM
- New REDUCE-IT Data in Patients at Extreme Cardiovascular Risk and In Vitro Research on the Mechanistic Effects of Eicosapentaenoic Acid (EPA) on Lipoprotein(a) [Lp(a)] Oxidation to be Presented at the American College of Cardiology’s (ACC) Annual Scienti • GlobeNewswire Inc. • 03/16/2026 12:15:00 PM
- Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405] • Edgar (US Regulatory) • 03/02/2026 10:31:01 PM
- Effects of Icosapent Ethyl on Risk and Duration of Hospitalizations and Death in REDUCE-IT® Post Hoc Analysis Published in the European Journal of Preventive Cardiology • GlobeNewswire Inc. • 03/02/2026 01:00:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 02/25/2026 12:05:26 PM
- Amarin Reports Fourth Quarter and Full Year 2025 Financial Results • GlobeNewswire Inc. • 02/25/2026 12:00:00 PM
- This American Heart Month Amarin Spotlights the Need to Prioritize Proven Widely Available Yet Underutilized Therapies in the Battle Against Cardiovascular Disease • GlobeNewswire Inc. • 02/23/2026 01:00:00 PM
- Amarin to Report Fourth Quarter and Full Year 2025 Financial Results and Host Conference Call on February 25, 2026 • GlobeNewswire Inc. • 02/11/2026 01:00:00 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 02/04/2026 12:00:09 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 02/04/2026 12:00:07 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 02/04/2026 12:00:06 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 02/04/2026 12:00:05 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 02/04/2026 12:00:04 AM
- Amarin Applauds Breakthroughs In Therapies For Patients With Elevated Triglycerides; Company’s VASCEPA®/VAZKEPA® (Icosapent Ethyl) Franchise Well Positioned To Benefit Globally From Broadened Category Commercialization • GlobeNewswire Inc. • 01/09/2026 12:00:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 01/08/2026 12:05:27 PM
- Amarin Announces Preliminary 2025 Financial Highlights and Operational Accomplishments, Including Achieving Positive Cash Flow; Company Well Positioned to Capture Global Growth Opportunities • GlobeNewswire Inc. • 01/08/2026 12:00:00 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 01/06/2026 10:00:21 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 01/06/2026 10:00:17 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 01/06/2026 10:00:10 PM
